Loading stock data…
IBIO
$1.59-0.10 (-5.92%)
Market ClosedLast close May 1
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
iBio, Inc. in the Healthcare sector is trading at $1.59. The stock is currently 58% below its 52-week high of $3.82, remaining 1.9% above its 200-day moving average. Technical signals show oversold RSI of 13 and bearish MACD signal, explaining why IBIO maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 13) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.59
Potential Upside
5%
Whystock Fair Value$1.67
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved C...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$66.14M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.74%
Volume
Today's trading volume
693,442
Recent News
iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600
iBio Inc. (NASDAQ:IBIO) is one of the best NASDAQ growth stocks to buy and hold forever. On April 8, iBio received regulatory clearance and ethics approval to initiate its first-in-human Phase 1 clinical trial of IBIO-600 in Australia. This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics of the therapy in overweight […]
iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”
iBio (NASDAQ:IBIO) is seeking to narrow what it views as a growing “trust gap” between the promise of generative AI in drug discovery and the high cost and long timelines of bringing a drug to market, according to Alex Taguchi, the company’s Director of Machine Learning. In a webinar presentation on
iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3
Executives at iBio (NASDAQ:IBIO) outlined the scientific and strategic rationale for a myostatin/activin A bispecific antibody program that the company believes could become a next-generation therapy for heart failure, with an initial focus on pulmonary hypertension associated with heart failure wit
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.